Gabriele Cerrone Buys 5,000 Shares of Tiziana Life Sciences PLC (LON:TILS) Stock

Tiziana Life Sciences PLC (LON:TILS) insider Gabriele Cerrone acquired 5,000 shares of the business’s stock in a transaction that occurred on Monday, June 10th. The shares were purchased at an average cost of GBX 75 ($0.98) per share, with a total value of £3,750 ($4,900.04).

Gabriele Cerrone also recently made the following trade(s):

  • On Friday, May 31st, Gabriele Cerrone acquired 5,000 shares of Tiziana Life Sciences stock. The shares were purchased at an average cost of GBX 57 ($0.74) per share, with a total value of £2,850 ($3,724.03).
  • On Wednesday, May 1st, Gabriele Cerrone acquired 10,000 shares of Tiziana Life Sciences stock. The shares were purchased at an average cost of GBX 60 ($0.78) per share, with a total value of £6,000 ($7,840.06).

TILS opened at GBX 71 ($0.93) on Thursday. Tiziana Life Sciences PLC has a twelve month low of GBX 36 ($0.47) and a twelve month high of GBX 148 ($1.93). The company has a debt-to-equity ratio of 59.12, a current ratio of 1.08 and a quick ratio of 1.03. The stock has a market cap of $96.89 million and a P/E ratio of -15.11.

TRADEMARK VIOLATION NOTICE: “Gabriele Cerrone Buys 5,000 Shares of Tiziana Life Sciences PLC (LON:TILS) Stock” was first posted by Modern Readers and is owned by of Modern Readers. If you are reading this report on another site, it was stolen and reposted in violation of US & international copyright law. The legal version of this report can be accessed at https://www.modernreaders.com/news/2019/06/13/gabriele-cerrone-buys-5000-shares-of-tiziana-life-sciences-plc-lontils-stock-2.html.

About Tiziana Life Sciences

Tiziana Life Sciences Plc, a clinical stage biotechnology company, focuses on the discovery and development of molecules and related diagnostics to treat diseases in oncology and immunology in the United Kingdom. The company's product pipeline includes Foralumab (TZLS-401), a human anti-CD3 monclonal antibody for the treatment of autoimmune and inflammatory diseases, such as non-alcoholic steatohepatitis, Crohn's disease, multiple sclerosis, type-1 diabetes, inflammatory bowel diseases, psoriasis, and rheumatoid arthritis; and Milciclib (TZLS-201), which is an orally bioavailable, small molecule inhibitor of cyclin-dependent kinases and Src family kinases for the treatment of hepatocellular carcinoma.

Recommended Story: Straddles

Insider Buying and Selling by Quarter for Tiziana Life Sciences (LON:TILS)

Receive News & Ratings for Tiziana Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tiziana Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.